Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

NCT00909025 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Claudiximab

Sponsor

Ganymed Pharmaceuticals GmbH